5,953,639 Restricted cash100,651–– Accounts receivable778,769258,855 Inventories, net1,024,25039,970 Prepaid expenses and other current assets176,259138,712Total current assets4,289,8706,391,176Property and equipment, net1,191,840441,996Other assets334,85557,982 Total assets$
6,891,154Liabilities and Stockholders' Equity (Deficit)Current liabilities: Accounts payable$
1,240,397 Accrued rent98,05710,493 Accrued payroll268,686241,586 Accrued severance pay18,260371,596 Accrued vacation153,155117,619 Deferred revenue25,000–– Warranty reserve36,850–– Accrued other expenses293,590157,699 Current portion of long-term debt419,38421,663Total current liabilities2,509,8432,161,053Long-term debt, net of current portion1,589,4688,852Put option derivative liability194,088—Warrant derivative liability2,240,9622,778,191Redeemable convertible preference shares in subsidiary3,337,4763,290,994Commitments and contingencies——Stockholders' equity (deficit): Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding—— Common Stock: $0.001 par value; 300,000,000 shares authorized; 41,175,464 and 33,387,857 shares issued and outstanding at December 31, 2010 and December 31, 200941,17533,388 Additional paid-in capital38,881,07529,017,578 Deficit accumulated during the development stage(43,265,399)(30,462,283) Accumulated other comprehensiv
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved